Drug Trial Radar · NCT05283330
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Dec 22, 2022
Primary completion
Jan 2027
Study completion May 2032
Sponsor
- Lead sponsor
- Orano Med Theranostics, SASIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Conditions
- Cervical Cancer
- Breast Cancer
- Colon Cancer
- NSCLC
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Glioblastoma
- Nonsmall Cell Lung Cancer
Interventions
²¹²Pb-DOTAM-GRPR1Drug
²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the Recommended Phase 2 Dose (RP2D) of ²¹²Pb-DOTAM-GRPR1Time frame: 14 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Northwestern University Robert H Lurie Medical Research
Chicago, Illinois
University of Iowa Health Care
Iowa City, Iowa
UK Markey Cancer Center
Lexington, Kentucky
Advanced Molecular Imaging and Therapy
Glen Burnie, Maryland
United Theranostics - Chesapeake
Glen Burnie, Maryland
Nebraska Cancer Specialists (Midwest Cancer Center - Legacy)
Omaha, Nebraska
XCancer Omaha / Urology Cancer Center
Omaha, Nebraska
University of Pittsburg Medical Center (UPCM)
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.